Phase II trial of 5‐fluorouracil, adriamycin, mitomycin C, and streptozotocin (FAM‐S) in pancreatic carcinoma

R. M. Bukowski, L. P. Schacter, C. W. Groppe, J. S. Hewlett, J. K. Weick, R. B. Livingston

Research output: Contribution to journalArticle

23 Scopus citations

Abstract

Twenty‐five patients with unresectable and metastatic pancreatic carcinoma were treated with the combination of 5‐fluorouracil, Adriamycin, mitomycin C and streptozotocin (FAM‐S). Twelve of 25 patients responded (48%) and four patients demonstrated stable disease. Median survival of all patients was 6.75 months, and seven of 25 patients survived more than 12 months. Hematologic toxicity was moderate, and the predominant side effect recorded was nausea and vomiting (80% patients). Combination chemotherapy in pancreatic carcinoma may provide palliation and randomized trials are warranted to confirm these results.

Original languageEnglish (US)
Pages (from-to)197-200
Number of pages4
JournalCancer
Volume50
Issue number2
DOIs
StatePublished - Jul 15 1982

    Fingerprint

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this